[{"id":"e9e77af0-89f1-42d4-a03f-cc0813b452ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT06027086","created_at":"2023-09-07T16:09:42.798Z","updated_at":"2025-02-25T13:41:42.827Z","phase":"Phase 1/2","brief_title":"DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","source_id_and_acronym":"NCT06027086","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" DNAJB1 • PRKACA","pipe":" | ","alterations":" DNAJB1-PRKACA fusion","tags":["DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • sirpiglenastat (DRP-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2033","study_completion_date":" 09/01/2033","last_update_posted":"2025-02-21"}]